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In the present study, we examined the effects of central administration of Urotensin
II on blood pressure, heart rate, and baroreceptor heart rate reflexes in conscious
normotensive rabbits. Preliminary operations were undertaken to implant a balloon cuff
on the inferior vena cava for baroreflex assessments and to implant cannula into the
lateral and fourth ventricle. After 2 weeks of recovery cumulative dose response curves to
Urotensin II (10, 100 ng, 1, 10, and 100µg) given into the ventricles, or Ringer’s solution
as a vehicle were performed on separate days. Injections were given each hour and
baroreflex assessments were made 30 min after each administration. Analysis of the
dose response curves to Urotensin II compared to vehicle administered into the lateral or
fourth ventricle, indicated little change to blood pressure or heart rate. Analysis of the time
course to the highest dose over a 30 min period revealed a small (−5 mmHg) depressor
response maximal at 10 min when injected into the fourth ventricle but no effect when
injected into the lateral ventricle. Baroreflex assessments made at each dose showed that
there was no change in baroreflex sensitivity but that an increase in the upper plateau
was observed when Urotensin was injected into the lateral ventricle and a tendency for
a reduced lower heart rate plateau was observed after fourth ventricle administration.
Clonidine administration in the fourth ventricle decreased blood pressure and heart rate,
thus confirming catheter patency. In conclusion, our findings suggest that Urotensin II in
the forebrain and brainstem may play a role in modulating cardiac sympathetic and vagal
baroreflexes but only during large acute changes in blood pressure.
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INTRODUCTION
The cyclic dodecapeptide Urotensin II is a powerful agent to affect arteries (Ames et al., 1999;
Maguire and Davenport, 2002). Urotensin II and its G-protein-coupled receptor, GPR14 are
both expressed within the mammalian vasculature (Douglas and Ohlstein, 2000). It has been
found that activation of GPR14 by Urotensin II results in a constriction of isolated blood vessels
which is dependent on both species and anatomical origin, making Urotensin II an efficacious,
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sustained spasmogen of non-mammalian and mammalian
isolated blood vessels (Nothacker et al., 1999; Douglas
and Ohlstein, 2000; Douglas et al., 2000; MacLean et al.,
2000; Maguire et al., 2000; Maguire and Davenport, 2002).
Physiological role of Urotensin II includes induction of
vasoconstriction, migration, and proliferation of vascular
smooth muscle cell and control of cardiac output. Urotensin II
is also linked in the progression of atherosclerosis, many types
of cardiac disease, renal disease, and metabolic syndrome (Ross
et al., 2010). In this regard, the cyclic structure of the peptide
which is responsible for its biological action has been highly
conserved from fish to mammals (Douglas and Ohlstein, 2000;
Ross et al., 2010). In vivo studies showmarked species differences
in the actions of intravenously administered Urotensin II. In
the rat, intravenous Urotensin II elicits a depressor response
due to mesenteric and hindquarter vasodilatation associated
with tachycardia (Gardiner et al., 2001; Lin et al., 2003). By
contrast administration of Urotensin II to primates produces a
powerful vasoconstriction (Ames et al., 1999) but blood pressure
falls dramatically due to a cardiac depressor action. In humans,
intravenous Urotensin II has no significant vasoconstrictor or
vasodilator action on arteries or veins of small or medium caliber
(Hillier et al., 2001).
There is now evidence to suggest that Urotensin II may
play a role within the central nervous system (CNS) (Conlon
et al., 1996; Chartrel et al., 1998). More specifically, GPR14
has been discovered in nuclei throughout the brain of many
different species including rats (Dun et al., 2001), frogs
(Coulouarn et al., 1998), and humans (Coulouarn et al., 1998).
Immunohistochemistry has revealed that Urotensin II is found
in the soma of cholinergic motoneurons (Dun et al., 2001).
While some of the regions are involved in control of muscles,
others such as the dorsal motor nucleus of the vagus and the
nucleus ambiguous are known to be the source of cardiac vagal
motor neurons and may play a role in regulating heart rate
and therefore possibly cardiovascular reflexes. While studies so
far suggest that Urotensin in the brain is likely to play a role
in cardiovascular regulation, its precise role is not clear. In
conscious rats pressor and tachycardic actions of Urotensin II
have been reported (Lin et al., 2003) but in anesthetized rats,
Urotensin II causes hypotension and bradycardia (Gibson et al.,
1986). Direct microinjection of Urotensin II into the region of
the brainstem of rats produced hypotension and bradycardia but
no effect was observed when injected into the A2 region of the
dorsomedial medulla (Lu et al., 2002). By contrast, microinjection
into the forebrain nuclei such as the paraventricular or the
arcuate nucleus evokes large increases in blood pressure and
heart rate (Lu et al., 2002). Furthermore, studies in sheep show
that ICV administration of small doses of human Urotensin
II to sheep produces a long lasting increase in cardiac output,
heart rate and blood pressure accompanied by increasing levels
of stress and alerting hormones but little effect on vascular
resistance (Watson et al., 2003). To date however there have
been no reports of central administration of Urotensin II on
cardiovascular reflexes. Furthermore, studies so far on its central
actions have been limited to rats and sheep. Thus, the presence of
the peptide and its receptors in pre-autonomic brain regions led
us to hypothesize that the central administration of Urotensin II
will affect the autonomic control of cardiovascular variables in
the conscious rabbits. Hence, the aim of the current study was to
investigate the effects of central Urotensin II on cardiovascular
parameters and the baroreceptor heart rate reflexes in another
species, namely conscious normotensive rabbits. The reflex is
well-characterized in this species (Korner et al., 1972) being
largely mediated by changes to cardiac vagus activity unlike
the rat which has a larger sympathetic component (Head and
McCarty, 1987). In addition, we examined both lateral ventricle
and fourth ventricular administration to separate forebrain from
hindbrain actions.
MATERIALS AND METHODS
Animals
Experiments were conducted in five naïve female rabbits and
one male rabbit, bred from stock and housed at the Baker
Heart and Diabetes Research Institute and whose weight ranged
from 2.5 to 3.5 kg. Female rabbits are induced ovulators and
as such do not undergo an estrous cycle (Adams and Ratto,
2013). In this regard, there are few if any differences in the
cardiovasvular responses between sexes. The colony was derived
from an original multi-colored English strain with “Dutch
Belted.” Prior to surgery and post-operatively each animal was
housed in individual standard rabbit cages, under conditions of
constant ambient temperature, constant humidity and normal
light/dark cycle (with the lights on from 0700 to 1900). Food
and water were accessible ad libitum for the duration of the
study. All procedures were approved by the Alfred Medical
Research Education Precinct Animal Ethics Committee and
conducted in accordance with the Australian Code of Practice
for Scientific Use of Animals (Australian Code of Practice for
the Care and Use of Animals for Scientific Purposes 7th Edition,
2004).
Surgical Preparation
All animals underwent three separate surgical operations
performed under halothane Pharmachem, Australia) after
induction with intravenous administration of propofol
(10mg/kg).
During the first procedure, a small perivascular silastic balloon
was implanted around the intrathoracic inferior vena cava
through a right thoracotamy while the rabbit was artificially
ventilated. The exterior extremity of the tubing attached to the
balloon was sutured under the skin between the scapulae. The
lungs were reinflated, air removed from the chest cavity, the ribs
drawn tightly together and the muscle and skin sutured.
Two weeks after the initial surgery, the six rabbits underwent
a second surgical procedure. An intracerebroventricular catheter
(Plastics One, Roanoke, VA, USA) was implanted into the lateral
ventricle (coordinates from bregma; −3 mm lateral and −4 mm
ventral) as described previously (Head and Williams, 1992).
Following the recovery period from the first two procedures, a
fourth ventricular catheter was implanted as described previously
(Head et al., 1983). Briefly, the atlanto-occipital membrane was
exposed, and a small hole made with a 25G needle. A small
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FIGURE 1 | Log dose response curves for Urotensin II and vehicle
showing the changes in the baroreflex cardiovascular parameters of
systolic blood pressure (SBP, mmHg), diastolic blood pressure (DBP,
mmHg), mean blood pressure (MBP, mmHg), and heart rate (HR, beats
per min), expressed relative to the initial control parameters. Error bars
are SEM indicating animal variance between doses within groups.
vinyl catheter was inserted 8 mm through the hole allowing the
tip to lie along the floor of the fourth ventricle. The end of the
catheter was buried subcutaneously at the back of the rabbit’s
neck.
Drugs
The drugs used were Human Urotensin II (Servier, Australia), L-
phenylephrine HCl (Sigma Company, Australia), and clonidine
HCl (Boehringer Ingelheim Pty Ltd, Australia). The doses of
drugs were expressed inµg of the base. Drugs administered
into the lateral ventricle or fourth ventricle were dissolved in
Ringer’s (Baxter, Old Toongabbie, NSW, Australia) solution
while drugs given i.v. were dissolved in normal saline (Baxter, Old
Toongabbie, NSW, Australia).
TABLE 1 | Effects of treatment with Urotensin II administered in the fourth
or lateral ventricles on cardiovascular parameters.
Dose (µg) Significance
0.01 0.1 1.0 10.0 100 SEM Linear
trend
Difference
from Veh
VEHICLE
Systolic BP (mmHg) 2.9 7.3 5.4 0.7 4.0 1.9 NS
Diastolic BP (mmHg) 1.8 0.1 −1.9 −4.3 −3.1 1.4 NS
Mean BP (mmHg) 1.3 0.8 −1.2 −4.6 −3.0 1.3 NS
HR (b/min) 15.6 21.2 28.8 32.2 32.0 3.9 NS
LATERAL VENTRICLE
Systolic BP (mmHg) −0.6 −1.6 −0.9 0.5 1.6 1.9 NS NS
Diastolic BP (mmHg) 1.4 −0.1 0.9 −0.1 2.6 1.4 NS NS
Mean BP (mmHg) 0.4 −1.2 −0.4 −1.2 1.0 1.3 NS NS
HR (b/min) 6.1 12.2 21.2 25.4 33.3 3.9 ** NS
FOURTH VENTRICLE
Systolic BP (mmHg) 0.9 2.1 6.3 2.1 −1.0 1.9 NS NS
Diastolic BP (mmHg) 0.4 0.8 −0.1 −0.1 −2.1 1.4 NS NS
Mean BP (mmHg) −0.1 0.6 1.0 −0.3 −2.9 1.3 NS NS
HR (b/min) 13.9 12.6 18.4 18.8 20.7 3.9 NS NS
Data expressed compared to control. Values are mean and SEM indicating within animal
variance. Significance: **P < 0.01, NS, P > 0.05.
Experimental Procedures
Experiments were conducted in conscious rabbits held in
a standard single rabbit holding box. Arterial pressure was
measured from the central ear artery which was catheterized
transcutaneously (Burke and Head, 2003).
Pulsatile arterial blood pressure was measured with a Statham
P23ID strain gauge pressure transducer (Statham, Hato Rey,
Puerto Rico) and HR was derived by a rate-meter triggered
from the arterial pulse. Mean arterial pressure (MAP), HR
and respiration rate were digitized and averaged over 2 s
periods by computer using the LabVIEW programming language
(National Instruments, Austin, TX, USA). Throughout the
experiment, cardiovascular parameters were recorded on a six-
channel polygraph (Grass Instruments, model 7D, Quincy,
Massachusetts, USA).
Experimental Design
Protocol
The first experiment was conducted at least 14 days after
implantation of the fourth ventricle catheter. Each rabbit
underwent three experiments, each separated by 2 week recovery,
during which a dose response curve to either Urotensin II into the
lateral ventricle, Urotensin II into the fourth ventricle or a control
experiment was performed which consisted of administering the
same volumes of Ringer’s solution (either via lateral or fourth
ventricle). For each experiment, there was an initial 30 min
acclimatization period and a 30min period during which baseline
baroreflex parameters were obtained in duplicate. Dose-response
curves were performed using a range of five increasing doses of
Urotensin II administered in 25µL. The doses were 10 ng (7
pmol), 100 ng (72 pmol), 1µg (0.7 nmol), 10µg (7 nmol), and
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FIGURE 2 | Average systolic (black), mean (white) and diastolic (gray)
arterial pressure (mmHg) and heart rate (b/min) before (control) and
after 100µg Urotensin II administered into the lateral ventricle (A) and
into the fourth ventricle (B) in six conscious rabbits (arrow at time 0). *Indicates
P < 0.05 compared to control. Error bars indicate the SEM between animals.
100µg (72 nmol) and thus covered 4 orders of magnitude. The
dose range was based on a previous publication (Lin et al., 2003).
Each dose was separated by a 60 min recording period during
which a single ramp baroreflex assessment was made (between
30 and 45 min). The order of experiments was randomized and
only one dose response curve was performed in the animal per
experiment.
The HR baroreflexes were derived from slow ramp rises and
falls in MAP by i.v. infusion of 0.5 mg/ml phenylephrine and
inflation of the vena caval cuff respectively (Gaudet et al., 2000).
At the conclusion of the third and final experiment for each
animal, 5µg/kg of clonidine was administered via the fourth
ventricle to ensure the catheter was implanted correctly (Head
et al., 1983).
Data Analysis
Hemodynamic Data
Data was averaged over at least 10 min for the control periods,
and 30 min following administration of the treatment.
Analysis of Baroreflex Curves
MAP and HR were averaged over 2 s intervals and fitted to
a sigmoid logistic function to produce MAP-HR curves as
described previously (Ricketts and Head, 1999). We used a non-
linear regression program utilizing the Marquardt-Levenberg
method to estimate a lower plateau which is minimum RSNA or
HR, the HR range between upper plateau (which is a calculated
maximum activation) and lower plateau, an upper and lower
parameter defining the curvature and the median blood pressure
or MAP at half the reflex range (BP50) (Ricketts and Head,
1999). The average range-dependent gain of the curve (G) was
calculated HR range x curvature/4.
Statistical Analysis
Values were expressed as mean ± standard error of the mean
(SEM) or mean difference ± standard error of the difference
(SED). For all parameters, a repeated measure ANOVA was
performed on the change (delta) from control values. The
between treatment sums of squares was partitioned into two non-
orthogonal contrasts comparing each treatment with vehicle. In
addition, the between doses sums of squares was partitioned into
a linear trend (indicating a dose response relationship) and the
non-linear component. A Bonferroni adjustment of the t statistic
was made to account for the multiple testing and lessen the
likelihood of a type 1 error.
RESULTS
Basal Cardiovascular Measurements
There were no differences in MAP or HR with Urotensin II
injection into the lateral ventricle, into the fourth ventricle and
control experiment over time (83.6 ± 4.1, 88.2 ± 5.4, and
81.6 ± 3.9 mmHg for MAP, 188 ± 5.3, 211.5 ± 14.6, and
207± 10.4 b/min for HR, respectively).
Urotensin Dose Response Curves
Increasing doses of Urotensin II administered into the fourth
ventricle did not alter any of the cardiovascular parameters
measured (Figure 1). While lateral ventricle administration of
Urotensin II did not alter blood pressure, we did observe a dose
dependent increase in HR (Figure 1, F1, 70 linear trend = 12,
P < 0.01). The analysis of variance showed no difference in the
effect of Urotensin on HR compared to vehicle administration
(Figure 1, Table 1). This was because there was a tendency for
HR to be elevated during the experiments compared to control
for all treatments (average+26 b/min for vehicle,+20 b/min for
lateral ventricle Urotensin and +17 b/min for fourth ventricle
Urotensin).
Time Course of 100µg Urotensin II
Urotensin II into the lateral ventricle (1MAP = −0.5
± 0.8mmHg) had no effect on blood pressure at any
time within the 30 min period examined (Figure 2A). By
contrast, this dose of Urotensin II administered into the fourth
ventricle produced a small but clear hypotensive response
(1MAP = −4.8 ± 1.0mmHg, P < 0.001, Figure 2B) which
reached a maximum at 10 min.
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Effect of Urotensin of Baroreceptor HR
Reflexes
Baroreflex assessments were made by using the rapid ramp
method before and 30 min after each dose of Urotensin or
vehicle. The blood pressure set-point (BP50) and the baroreflex
sensitivity (average gain) did not change over the course of
the experiment with repeated assessments during either the
Urotensin II or vehicle administration protocols (Figure 3,
Table 2). However, we did observe a lower HR range due
to a change in the lower HR plateau in the animals given
fourth ventricular Urotensin II (P < 0.01, Figure 3, Table 2).
This effect occurred at all doses examined since there was no
clear dose response relationship observed. Increasing doses of
Urotensin II into the lateral ventricle increased the upper plateau
FIGURE 3 | Log dose response curves for Urotensin II and vehicle showing the changes in the baroreflex parameters of lower plateau (beats per
minute), average curvature (100mmHg−1), range (beats per min), average gain (beats per min per mmHg), upper plateau (beats per min), and BP50
(mmHg) expressed relative to the initial control parameters. *Indicates P < 0.05, **P < 0.01.
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TABLE 2 | Effects of treatment with Urotensin II administered in the fourth
or lateral ventricles on baroreflex parameters.
Dose (µg) Significance
0.01 0.1 1.0 10.0 100 SEM Linear
trend
Difference
from Veh
VEHICLE
Upper Plateau
(b/min)
19.5 15.7 13.3 17.9 11.7 4.9 NS
Range (b/min) 7.3 14.1 9.4 5.3 21.0 7.6 NS
Lower Plateau
(b/min)
12.1 1.7 3.8 12.6 −9.3 6.2 NS
BP50 (mmHg) 1.1 −0.9 3.7 2.5 −0.1 2.1 NS
Av. Gain
(b/min/mmHg)
0.5 0.0 −1.3 −0.3 −1.1 0.7 NS
Av. Curvature x
100 (mmHg −1)
2.0 1.3 −1.4 −0.3 0.2 1.4 NS
LATERAL VENTRICLE
Upper Plateau
(b/min)
11.4 14.2 19.0 28.7 32.5 4.9 * NS
Range (b/min) 5.6 22.5 7.3 19.2 27.3 7.6 NS NS
Lower Plateau
(b/min)
5.8 −8.3 11.7 9.5 5.2 6.2 NS NS
BP50 (mmHg) −0.5 3.8 0.8 3.2 6.4 2.1 NS NS
Av. Gain
(b/min/mmHg)
−1.7 −0.4 −0.6 −0.3 −0.2 0.7 NS NS
Av. Curvature x
100 (mmHg −1)
−3.7 0.5 −1.2 0.4 0.8 1.4 NS NS
FOURTH VENTRICLE
Upper Plateau
(b/min)
7.6 9.6 9.7 4.0 10.4 4.9 NS NS
Range (b/min) −19.3 −4.3−19.9−18.0−11.7 7.6 NS ***
Lower Plateau
(b/min)
26.9 13.8 29.6 22.0 22.1 6.2 NS **
BP50 (mmHg) 5.8 2.5 2.5 2.5 3.3 2.1 NS NS
Av. Gain
(b/min/mmHg)
0.7 0.7 −0.3 1.5 −0.7 0.7 NS NS
Av. Curvature x
100 (mmHg −1)
−0.1 0.7 −2.3 1.9 −2.8 1.4 NS NS
Data expressed compared to control. Values are mean and SEM indicating within animal
variance. Significance: *P < 0.05, **P < 0.01, ***P < 0.001, NS, P > 0.05.
of the baroreflex curve (F1, 70 linear trend = 5.3, P < 0.05,
Figure 3).
The lower HR plateau was reduced after 1µg Urotensin II into
the fourth ventricle compared to the control (P < 0.05, Figure 4)
whereas with 10 and 100µg doses, there was a borderline
significance when compared to the control (P = 0.07, Figure 5).
With the highest doses of Urotensin II given into the lateral
ventricle (10 and 100µg) we did observe there a significant
increase in the upper HR plateau of the curve compared to the
control curves (P < 0.05 and 0.01, respectively, Figure 5).
Effect of Clonidine
To confirm the patency of the fourth ventricular catheter
clonidine was administered at the end of the last experiment in all
6 animals. Administration of 5µg/kg of clonidine into the fourth
FIGURE 4 | The effect of 1 µg Urotensin II or vehicle in the fourth and
lateral ventricles on the baroreflex curve averaged for 6 rabbits as
compared to control. *Indicates P < 0.05.
ventricle elicited a rapid reduction in HR and blood pressure
(Figure 6) in all animals tested.
DISCUSSION
The main findings of the present study were that Urotensin II
administered into the fourth or lateral ventricle of conscious
rabbits differentially affected the maximum and minimum
plateaus of the baroreceptor HR reflex with few other
changes observed to arterial pressure or HR. We observed a
small depressor response to 100µg Urotensin II administered
into the fourth ventricle but the small increases in HR
were not related to a specific effect of Urotensin II. The
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FIGURE 5 | The effect of 10 µg Urotensin II or vehicle (Left) in the fourth and lateral ventricles and the effect of 100 µg Urotensin II or vehicle (Right) on the
baroreflex curve averaged for 6 rabbits as compared to control. (*)Indicates P = 0.06, *indicates P < 0.05, **indicates P < 0.01.
lateral ventricle administration increased the upper plateau of
the HR curves which is where the sympathetic activity is
maximally activated during hypotension. By contrast, the fourth
ventricular administration inhibited the lower plateau which
is predominately the vagal end of the curve. Taken together
these results suggest that central administration of Urotensin
II modifies autonomic control of heart rate but only when
these reflex systems are responding close to maximal changes in
blood pressure. Interestingly, the forebrain action of Urotensin
II appears to facilitate the maximum cardiac sympathetic activity
while the hindbrain action appears to be to inhibit the maximum
cardiac vagal activity. The combined action would be to shift the
curve upward.
To our knowledge, this is the first report of a central effect
of Urotensin II on autonomic reflexes in conscious rabbits.
It has been shown that autoradiographic labeling of brain
slices indicate the presence of urotensin II binding sites in
the lateral septum, bed nucleus of the stria terminalis, medial
amygdaloid nucleus, anteroventral thalamus, anterior pretectal
nucleus, pedunculopontine tegmental nucleus, pontine nuclei,
geniculate nuclei, parabigeminal nucleus, dorsal endopiriform
nucleus, and cerebellar cortex (Jégou et al., 2006). Importantly,
Urotensin II immunoreactive cell bodies in the brainstem have
shown dense labeling in the dorsal motor nucleus of the vagus
and also the nucleus ambiguous among others (Dun et al., 2001).
This would be a likely location for the actions of Urotensin
II on the baroreflex as these are important areas involved in
the vagal control of heart rate and suggests that Urotensin II
as a possible neuromodulator through an autoreceptor, inhibits
the cardiac vagus when they are most active. Clearly, the
distribution of Urotensin II needs to be confirmed in the rabbit
and electrophysiological studies would be necessary to confirm
this hypothesis.
Previous studies examining the central cardiovascular actions
of Urotensin II have been performed so far only with rats (Lin
et al., 2003; Brailoiu et al., 2014), sheep (Watson et al., 2003), and
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FIGURE 6 | Average systolic (black), mean (white) and diastolic (gray)
arterial pressure (mmHg) and heart rate (b/min) before (control) and
after 5µg/kg clonidine administered into the fourth ventricle (arrow at
time 0) of six conscious rabbits. *Indicates P < 0.05 compared to control.
Error bars indicate the SEM between animals.
conscious trout (Le Mevel et al., 1996; Vanegas et al., 2015). It
has been reported that in rainbow trout (Oncorhynchus mykiss),
central injection of Urotensin leads to aggression and anxiety-
like behavior (Backstrom et al., 2011). In conscious rats, central
administration of Urotensin II produces a short lasting (10–
20 min) dose dependent pressor response and tachycardia (Lin
et al., 2003) but in conscious sheep the tachycardia lasts for
several hours (Watson et al., 2003; Hood et al., 2005). In the
present study, we observed only a small depressor response
in conscious rabbits but with a time course similar to that
observed in conscious rats. The maximum dose we have used
(100µg= 72 nmol) is also similar on a per kg basis to those used
in rats (10 nmol) (Lin et al., 2003) but considerably larger than
that used in trout (0.5 nmol) (Le Mevel et al., 1996) and sheep
(8 nmol) (Watson et al., 2003). At this stage, we cannot rule out
that the small depressor response was due to a peripheral action
of Urotensin II. However, we did not observe any effect of lateral
ventricle administration of Urotensin II and while Urotensin II
constricts isolated arteries in rabbits (Saetrum Opgaard et al.,
2000) there have been no reports of systemic effects on blood
pressure reported in this species. Urotensin II given systemically
causes a biphasic response in sheep with an initial pressor
response followed by a long lasting depressor response (Watson
et al., 2003). By contrast in conscious rats Urotensin II produces
a rapid depressor responses (Douglas and Ohlstein, 2000). In
the rabbit, up to the very high doses we have used, there does
not appear to be any evidence for a central pressor response to
Urotensin II unlike other species. Indeed, the rabbit appears to
be unique (so far) in showing some limited depressor activity in
the hind brain.
In the present study we used the human form of Urotensin
II but across phyla from fishes to primates there is a great deal
of homology of the key cyclic region of the peptide which is
responsible for its biological action (Coulouarn et al., 1998). It
is unlikely that the relatively small changes we observed are
due to incompatibility between the human and rabbit forms of
the peptide since the human form has been used successfully
to constrict rabbit arteries (Saetrum Opgaard et al., 2000). In
conclusion, we suggest that Urotensin II in the forebrain and
brainstem may play an important role in modulating cardiac
sympathetic and vagal baroreflexes in rabbits.
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